You are on page 1of 5

Biocon

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of our first anti-cancer drug and several promising discovery partnerships in the clinic, we remain committed to scaling new heights in frontier science and achieving new milestones in affordable medicine.

The Innovation Matrix: A Strategic Framework

Our Innovation Matrix is a four-dimensional endeavour which extends into the realms of the known and the unknown. Creativity in the known realm builds on existing knowledge and can result in two types of innovation: INCREMENTAL and EVOLUTIONARY. Creativity that challenges unknown boundaries and creates new knowledge is EXPERIMENTAL and TRANSFORMATIONAL in its impact. A portfolio that covers all four spheres enables Biocon to sustain innovation in the short, medium and long term. Our biosimilar insulin, an outcome of incremental innovation, is one of the world’s most affordable therapies for insulin dependent diabetes. Bio-generic monoclonal antibodies are forming the core of our evolutionary innovation strategy. In the more challenging area of experimental innovation, Biocon is at the cutting edge. We are developing conjugated antibodies to potentially deliver therapeutic cancer vaccines. We are also pursuing a path of breakthrough innovation through global phase II human clinical trials to develop the world’s first Oral Insulin. Biocon is constantly traversing the path of delivering affordable therapeutics to the patients worldwide. Vision:
To promote social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services and educational opportunities.

Mission To be an integrated biotechnology enterprise of global distinction.

Essential to this mission is excellence in: - Intellectual asset creation through discovery, research and development - State-of-the-art manufacturing capabilities - Internationally benchmarked quality and regulatory systems - New medical insight through disease specific clinical research - Customer relationship through outstanding products and services - Human resource development through training, mentoring and empowering - Management of research and business partnerships

Awards:
Awards Kiran Mazumdar-Shaw has received several awards on behalf of Biocon and in her personal capacity as one of India's leading business entrepreneurs. Biocon: 2012 Biocon features in Top Twenty Global Employers in Biopharma by Science Magazine - Sept 21, 2012 Biocon wins Excellence in Environmental Management Award Biocon wins Best Exhibitor Award in the category of Biocontent and Information at Bangalore India Bio Biocon wins Golden Peacock National Quality Award 2011 Biocon wins Biospectrum BioPharma Company of the year award 2010 Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore India Bio

2009 Biocon among Top 20 Indian companies in Forbes ‘Best Under A Billion’ list. Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio Syngene wins Bio-Excellence Award for outstanding achievement in the Biotech Service Sector at Bangalore Bio Biocon bags IDMA "Best Patent of the year" award BIOMAb EGFR® was voted ‘Bio-Spectrum Asia-Pacific Product of the year’, 2008 Biocon wins prestigious BioSingapore Asia Pacific Biotechnology Award for Best Listed Company 2008 Biocon is ranked among the top 20 global biotechnology companies (Source: Med Ad News, June 2008) Biocon is the 7th largest biotech employer in the world (Source: Med Ad News, June 2008) CSR "We focus on disease prevention, improved healthcare facilities and child education. This three-pronged strategy will go a long way in improving the lives of India's rural communities."
– Rani Desai, Head Biocon Foundation

At Biocon, we believe our investment in better healthcare must go beyond developing new medicine to making medical assistance accessible to less advantaged, rural communities of India. Executing our corporate-social responsibility through the Biocon Foundation, we have adopted an integrated outreach strategy that focuses on social change and empowerment of rural communities through public health, sanitation and education programs. Biocon Foundation is a registered trust under the Indian Trusts Act of 1882, registration number is IV 410/06-07 dated August 9th, 2006. The trust is recognized under Section 80G of the Income Tax Act 1961.

Competitors: Aarey Drugs & Pharmaceuticals Ltd., Aanjaneya Lifecare Ltd., Aarti Drugs Ltd. Abbott India Ltd. ABL Bio-Technologies Ltd. Addlife Pharma Ltd.